Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Identifier:
ALXN1210-PNH-103
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: ALXN1210
Date
Nov 2015 - Jul 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: ALXN1210
Date
Nov 2015 - Jul 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.
Trial Locations
Location
Status
Location
Clinical Trial Site
Liverpool, New South Wales, Australia, 2170
Status
N/A
Location
Clinical Trial Site
Woolloongabba, Queensland, Australia, 4102
Status
N/A
Location
Clinical Trial Site
Seoul, Republic of Korea, 03080
Status
N/A
Location
Clinical Trial Site
Ulsan, Republic of Korea, 44033
Status
N/A